Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution but also increase access to life-saving products for people around the world.